Cannabis Science Inc. Brand Releases Worldwide Growth Guidance For Its Formulations Targeting Critical Ailments
Published: Dec 21, 2011
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to release its analysis of the worldwide market potential for medical cannabis treatments of critical ailments. There are three main markets for distribution, FDA approved prescriptions, OTC Non-psychoactive Neutroceuticals, and licensed dispensaries in legal Medical Marijuana states (currently 16). The Company has a patient oriented, holistic approach to healing with whole plant cannabis extract formulations. We are dedicated to working with Federal, State, and Local regulatory agencies, as well as similar agencies in other countries such as Health Canada, and other international regulatory bodies.